


I hereby certify that this paper is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on this date:

Dated: August 21, 2002

Signature: Andrew M. Lawrence

(Andrew M. Lawrence)



Docket No.: 27866/370A
(PATENT)

RECEIVED
AUG 27 2002
TECH CENTER 1601
7
DNT
9-20-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Donald E. Staunton

Application No.: 09/976,935

Group Art Unit: 1646

Filed: October 12, 2001

Examiner: Not Yet Assigned

For: Materials And Methods To Modulate Ligand
Binding/Enzymatic Activity Of Alpha/Beta
Proteins Containing An Allosteric Regulatory
Site

INFORMATION DISCLOSURE STATEMENT (IDS)

Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

The patents and/or publications listed on the enclosed PTO Form-1449 are submitted pursuant to 37 CFR §§ 1.56, 1.97, and 1.98. Copies of the patents or publications are enclosed as necessary.

This IDS is not intended to be an admission that a search has been made or that any of the documents constitute statutory prior art.

This statement and PTO-1449 form are submitted before receipt of a first Office Action in the above-identified patent application. Accordingly, the Applicant believes there are no fees due at this time. However, the Commissioner is hereby authorized to charge any deficiency in the amount enclosed or any additional fees which may be required to Deposit Account No. 13-2855. A duplicate of this paper is enclosed.

Dated: August 21, 2002

Respectfully submitted,

By: Andrew M. Lawrence

Andrew M. Lawrence, Reg. No. 46,130
MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 S. Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300
Attorneys for Applicant

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on this date:

Dated: August 21, 2002

Signature:


Andrew M. Lawrence
(Andrew M. Lawrence)

Docket No.: 2001/0012901

TECH CENTER 1000/2901

AUG 27 2002

RECEIVED



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Donald E. Staunton

Application No.: 09/976,935

Group Art Unit: 1646

Filed: October 12, 2001

Examiner: Not Yet Assigned

For: Materials And Methods To Modulate Ligand
Binding/Enzymatic Activity Of Alpha/Beta
Proteins Containing An Allosteric Regulatory
Site

INFORMATION DISCLOSURE STATEMENT (IDS)

Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

The patents and/or publications listed on the enclosed PTO Form-1449 are submitted pursuant to 37 CFR §§ 1.56, 1.97, and 1.98. Copies of the patents or publications are enclosed as necessary.

This IDS is not intended to be an admission that a search has been made or that any of the documents constitute statutory prior art.

This statement and PTO-1449 form are submitted before receipt of a first Office Action in the above-identified patent application. Accordingly, the Applicant believes there are no fees due at this time. However, the Commissioner is hereby authorized to charge any deficiency in the amount enclosed or any additional fees which may be required to Deposit Account No. 13-2855. A duplicate of this paper is enclosed.

Dated: August 21, 2002

Respectfully submitted,

By:

Andrew M. Lawrence

Andrew M. Lawrence, Reg. No. 46,130
MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 S. Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300
Attorneys for Applicant



RECEIVED

TECH CENTER 1600/2900

AUG 27 2002

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27866/36470ASerial No.
09/976,9

Applicant

Donald E. Staunton

Filing Date
10/12/01Group
1646

INFORMATION DISCLOSURE STATEMENT

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate
	A1	5,847,088	12/08/98	Cousens <i>et al.</i>	530	388.1	
	A2	5,888,809	03/30/99	Allison	435	325	
	A3	6,251,395	06/26/01	Gallatin <i>et al.</i>	424	144.1	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Aghazdeh <i>et al.</i> , "Structural Basis for Relief of Autoinhibition of the Dbl Homology Domain of Proto-Oncogene Vav by Tyrosine Phosphorylation," <i>Cell</i> , 102:625-633 (Sept. 1, 2000)
	C2	Amyes <i>et al.</i> , "Trimethoprim-Sensitivity Testing and Thymineless Mutants," <i>J. Med. Microbiol.</i> , 7(2):143-153 (1974)
	C3	Andersen <i>et al.</i> , "Protein export and drug efflux through bacterial channel-tunnels," <i>Curr. Opin. Cell Biol.</i> , 13:412-416 (2001)
	C4	Ausubel <i>et al.</i> , "Enzymatic Amplification of DNA by PCR: Standard Procedures and Optimization," <i>Curr. Protocols Mol. Biol.</i> , 3:15.1.1-15.1.14 (2001)
	C5	Baldock <i>et al.</i> , "A Mechanism of Drug Action Revealed by Structural Studies of Enoyl Reductase," <i>Science</i> , 274:2107-2110 (Dec. 20, 1996)
	C6	Berge <i>et al.</i> , "Pharmaceutical Salts," <i>J. Pharmaceutical Sciences</i> , 66(1):1-19 (Jan., 1977)
	C7	Bollag <i>et al.</i> , "Epothilones, a New Class of Microtubule-stabilizing Agents with a Taxol-like Mechanism of Action" <i>Cancer Research</i> , 55:2325-2333 (June 1, 1995)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



m PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 27866/36470A	Serial No. 09/976,9
INFORMATION DISCLOSURE STATEMENT				Applicant Donald E. Staunton	
				Filing Date 10/12/01	Group 1646

RECEIVED
AUG 27 2002
TECHNICAL CENTER 1600/2900

C8	Briesewitz <i>et al.</i> , "Expression of Native and Truncated Forms of the Human Integrin α_1 Subunit," <i>J. Biol. Chem.</i> , 268(4):2989-2996 (February 5, 1993)
C9	Chang <i>et al.</i> , "A general method for facilitating heterodimeric pairing between two proteins: Application to expression of α and β T-cell receptor extracellular segments," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 91:11408-11412 (November, 1994)
C10	Copley <i>et al.</i> , "Protein families in multicellular organisms," <i>Curr. Opin. Struct. Biol.</i> , 9:408-415 (1999)
C11	Couzin, "Integrin Crystal Structure Solved," <i>Science</i> , 293:1743-1746 (September 7, 2001)
C12	Cranmer <i>et al.</i> , "Glycoprotein (GP) Ib-IX-transfected Cells Roll on a von Willebrand Factor Matrix under Flow," <i>J. Biol. Chem.</i> , 274(10):6097-6106 (March 5, 1999)
C13	Crompton <i>et al.</i> , "Regulation of Tiam1 Nucleotide Exchange Activity by Pleckstrin Domain Binding Ligands," <i>J. Biol. Chem.</i> , 275(33):25751-25759 (August 18, 2000)
C14	deFougerolles <i>et al.</i> , "Regulation of inflammation by collagen-binding integrins $\alpha 1\beta 1$ and $\alpha 2\beta 1$ in models of hypersensitivity and arthritis," <i>J. Clin. Invest.</i> , 105(6):721-729 (March, 2000)
C15	De Vos <i>et al.</i> , "Three-Dimensional Structure of an Oncogene Protein: Catalytic Domain of Human c-H-ras p21," <i>Science</i> , 239:888-893 (February 19, 1988)
C16	Diamond <i>et al.</i> , "The I Domain Is a Major Recognition Site on the Leukocyte Integrin Mac-1(CD11b/CD18) for Four Distinct Adhesion Ligands," <i>J. Cell Biology</i> , 120(4):1031-1043 (February, 1993)
C17	Dickeson <i>et al.</i> , "Ligand recognition by the I domain-containing integrins," <i>Cell. Mol. Life Sci.</i> , 54:556-566 (1998)
C18	Didsbury <i>et al.</i> , "rac, a Novel ras-related Family of Proteins That Are Botulinum Toxin Substrates," <i>J. Biol. Chem.</i> , 264(28):16378-16382 (October 5, 1989)
C19	Edwards <i>et al.</i> , "The protein fold of the von Willebrand factor type A domain is predicted to be similar to the open twisted β -sheet flanked by α -helices found in human ras-p21," <i>FEBS Letter</i> , 358:283-286 (1995)
C20	Eliopoulos <i>et al.</i> , "Antimicrobial Combinations," in <i>Antibiotics in Laboratory Medicine</i> , 4 th Ed., pp. 330-396, (V. Lorian, ed., 1996)
C21	Emsley <i>et al.</i> , "Crystal Structure of the I Domain from Integrin $\alpha 2\beta 1$," <i>J. Biol. Chem.</i> , 272(45):28512-28517 (November 7, 1997)
C22	Emsley <i>et al.</i> , "Structural Basis of Collagen Recognition by Integrin $\alpha 2\beta 1$," <i>Cell</i> , 101:47-56 (March 31, 2000)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.	



Sheet 5 of 5

TECH CENTER 1600 2900

RECEIVED
AUG 27 2002

in PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 27866/36470A	Serial No. 09/976,9		
INFORMATION DISCLOSURE STATEMENT				Applicant Donald E. Staunton			
				Filing Date 10/12/01	Group 1646		

C23	Gibrat <i>et al.</i> , "Surprising similarities in structure comparison," <i>Curr. Opin. Struct. Biol.</i> , 6:377-385 (1996)
C24	Hahn <i>et al.</i> , "The complete sequences of plasmids pFNeo and pMN-Neo: convenient expression vectors for high-level expression of eukaryotic genes in hematopoietic cell lines," <i>Gene</i> , 127:267-268 (1993)
C25	Hardma <i>et al.</i> , eds., "Pharmacokinetics," Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, New York, New York, McGraw-Hill, Chapter 1, pp. 11-16 (1996)
C26	Higuchi <i>et al.</i> , eds., "Prodrug as Novel Drug Delivery Systems, ACS Symposium Series, 14, table of contents only (1975)
C27	Higuchi, "Prodrug and Drug Delivery - An Overview," Bioreversible Carriers in Drug Design Theory and Application, Roche ed., Pergamon Press, Chapter 1, pp. 1-12, (1987)
C28	Hitchings and Baccanari, "Design and Synthesis of Folate Antagonists as Antimicrobial Agents", in <i>Folate Antagonists as Therapeutic Agents</i> , Chapter 4, Vol. 1:151-172 (1984)
C29	Hua Jing <i>et al.</i> , "New structural motifs on the chymotrypsin fold and their potential roles in complement factor B," <i>EMBO J.</i> , 19(2):164-173 (2000)
C30	Huth <i>et al.</i> , "NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 97(10):5231-5236 (May 9, 2000)
C31	Kirshenbaum <i>et al.</i> , "Predicting allosteric switches in myosins," <i>Protein Science</i> , 8:1806-1815 (1999)
C32	Lee <i>et al.</i> , "Crystal Structure of the A Domain from the α Subunit of Integrin CR3 (CD11b/CD18)," <i>Cell</i> , 80:631-638 (February 24, 1995)
C33	Lochter <i>et al.</i> , " $\alpha 1$ and $\alpha 2$ Integrins Mediate Invasive Activity of Mouse Mammary Carcinoma Cells through Regulation of Stromelysin-1 Expression," <i>Mol. Biol. Cell</i> , 10:271-282 (February, 1999)
C34	Madej <i>et al.</i> , "Threading a Database of Protein Cores," <i>Proteins: Structure, Functions and Genetics</i> , 23:356-369 (1995)
C35	Mandell <i>et al.</i> , "Sulfonamides, Trimethoprim-Sulfamethoxazole, Quinolones, and Agents for Urinary Tract Infections," in <i>The Pharmacological Basis of Therapeutics</i> Chapter 44, Antimicrobial Agents, 1057-1072(Goodman and Gilman eds., 1996)
C36	Nelson <i>et al.</i> , "Matrix Metalloproteinases: Biologic Activity and Clinical Implications," <i>J. Clin. Oncol.</i> , 18(5):1135-1149 (March, 2000)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.	



For PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27866/36470ASerial No.
09/97635

Applicant

Donald E. Staunton

Filing Date
10/12/01Group
1646

INFORMATION DISCLOSURE STATEMENT

TECH. CENTER 1600/2900

AUG 27 2002

RECEIVED

C37	Nobes, "Rho GTPases and Cell Migration-Fibroblast Wound Healing," <i>Meth. Enzymol.</i> , 325:441-449 (2000)
C38	Nogales <i>et al.</i> , "Tubulin and FtsZ form a distinct family of GTPases," <i>Nature Structural Biology</i> , 5(6):451-458 (June, 1998)
C39	Oxvig <i>et al.</i> , "Conformational changes in tertiary structure near the ligand binding site of an integrin I domain," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 96:2215-2220 (March, 1999)
C40	Pozzi <i>et al.</i> , "Elevated matrix metalloprotease and angiostatin levels in integrin $\alpha 1$ knockout mice cause reduced tumor vascularization," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 97(5):2202-2207 (February 29, 2000)
C41	Ponting <i>et al.</i> , "SMART: identification and annotation of domains from signalling and extracellular protein sequences," <i>Nucl. Acids Res.</i> , 27(1):226-229 (1999)
C42	Poste <i>et al.</i> , "Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells," <i>Methods in Cell Biology</i> , Vol. XIV, Academic Press, New York, New York, Prescott, ed., Chapter 4, pp. 33-71 (1976)
C43	Qu <i>et al.</i> , "The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin," <i>Structure</i> , 4:931-942 (August 15, 1996)
C44	Rich <i>et al.</i> , "Trench-shaped Binding Sites promote Multiple Classes of Interactions between Collagen and the Adherence Receptors, $\alpha_1\beta_1$ Integrin and <i>Staphylococcus aureus</i> Can MSCRAMM," <i>J. Biol. Chem.</i> , 274(35):24906-24913 (August 27, 1999)
C45	Richey <i>et al.</i> , "The Biosynthesis of Folic Acid," <i>J. Biol. Chem.</i> , 244(6):1582-1592 (March 25, 1969)
C46	Rossmann <i>et al.</i> , "Bacterial Expressed DH and DH/PH Domains," <i>Meth. Enzymol.</i> , 325:25-38 (2000)
C47	Rost, "PHD: Predicting One-Dimensional Protein Structure by Profile-Based Neural Networks," <i>Meth. Enzymol.</i> , 266:525-539 (1996)
C48	Sadhu <i>et al.</i> , "LFA-1 Binding Site in ICAM-3 Contains a Conserved Motif and Non-Cotniguous Amino Acids," <i>Cell Adhes. Commun.</i> , 2:429-440 (1994)
C49	Scita <i>et al.</i> , "Signaling from Ras to Rac and beyond: not just a matter of GEFs," <i>EMBO J.</i> , 19(11):2393-2398 (2000)
C50	Schultz <i>et al.</i> , "SMART, a simple modular architecture research tool: Identification of signaling domains," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 95:5857-5864 (May, 1998)
C51	Schultz <i>et al.</i> , "SMART: a web-based tool for the study of genetically mobile domains," <i>Nucl. Acids Res.</i> , 28(1):231-234 (2000)
C52	Self <i>et al.</i> , "Purification of Recombinant Rho/Rac/G25K from <i>Escherichia coli</i> ," <i>Meth. Enzymol.</i> , 256:3-10 (1995)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.	



RECEIVED

AUG 27 2002

TECH CENTER 1600/2900

For mpep O-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27866/36470ASerial No.
09/976,

Applicant

Donald E. Staunton

Filing Date
10/12/01Group
1646

INFORMATION DISCLOSURE STATEMENT

C53	Shi <i>et al.</i> , "Bisubstrate Analogue Inhibitors of 6-Hydroxymethyl-7,8-dihydropterin Pyrophosphokinase: Synthesis and Biochemical and Crystallographic Studies," <i>J. Med. Chem.</i> , 44:1364-1371 (2001)
C54	Symons, "The Rac and Rho pathways as a source of drug targets for Ras-mediated malignancies," <i>Curr. Opin. in Biotech</i> , 6:668-674 (1995)
C55	John Wiley & Sons, Inc., "Classical Pathway Evaluation," Current Protocols in Immunology, Coligan <i>et al.</i> , eds. Vol. 3, Chapter 13, Unit 13.1 (2000)
C56	Velling <i>et al.</i> , "cDNA Cloning and Chromosomal Localization of Human α_{11} Integrin," <i>J. Biol. Chem.</i> , 274(36):25735-25742 (September 3, 1999)
C57	Worthylake <i>et al.</i> , "Crystal structure of Rac1 in complex with the guanine nucleotide exchange region of Tiam1," <i>Nature</i> , 408:682-688 (December 7, 2000)
C58	Young <i>et al.</i> , "Predicting conformational switches in proteins," <i>Protein Science</i> , 8:1752-1764 (1999)
C59	Yu <i>et al.</i> , "Ca ²⁺ -mediated GTP-dependent dynamic assembly of bacterial cell division protein FtsZ into asters and polymer networks <i>in vitro</i> ," <i>EMBO J.</i> , 16(17):5455-5463 (1997)
C60	"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, <i>National Committee Clinical Laboratory Standards Guidelines</i> , - 5 th Ed., Vol. 20, No. 2, pp. 1-27, Wayne, PA (January, 2000)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.